The interleukin-18 receptor (IL-18R) is an interleukin receptor of the immunoglobulin superfamily.[1][2]
Endometrial IL-18 receptor mRNA and the ratio of IL-18 binding protein to interleukin 18 are significantly increased in adenomyosis patients in comparison to normal people, indicating a role in its pathogenesis.[3]
References
- ^ Sergi B, Penttila I (2004). "Interleukin 18 receptor". J. Biol. Regul. Homeost. Agents. 18 (1): 55–61. PMID 15323361.
- ^ Wu C, Sakorafas P, Miller R, McCarthy D, Scesney S, Dixon R, Ghayur T (2003). "IL-18 receptor beta-induced changes in the presentation of IL-18 binding sites affect ligand binding and signal transduction". J. Immunol. 170 (11): 5571–7. doi:10.4049/jimmunol.170.11.5571. PMID 12759435.
- ^ Huang, H.; Yu, H.; Chan, S.; Lee, C.; Wang, H.; Soong, Y. (2010). "Eutopic endometrial interleukin-18 system mRNA and protein expression at the level of endometrial-myometrial interface in adenomyosis patients". Fertility and Sterility. 94 (1): 33–39. doi:10.1016/j.fertnstert.2009.01.132. PMID 19394601.
External links
|
---|
IL-1 |
- Antagonists: AF-12198
- Anakinra
- IL-1RA
- Isunakinra
- Antibodies: Canakinumab
- Gevokizumab
- Lutikizumab
- Decoy receptors: Rilonacept (IL-1 Trap)
|
---|
IL-2 |
- Agonists: Adargileukin alfa
- Aldesleukin
- Celmoleukin
- Denileukin diftitox
- Interleukin 2
- Pegaldesleukin
- Teceleukin
- Tucotuzumab celmoleukin
- Antibodies: Basiliximab
- Daclizumab (dacliximab)
- Inolimomab
|
---|
IL-3 | |
---|
IL-4 |
- Antibodies: Dupilumab
- Pascolizumab
|
---|
IL-5 |
- Antibodies: Benralizumab
- Mepolizumab
- Reslizumab
- Antisense oligonucleotides: TPI ASM8
|
---|
IL-6 |
- Antibodies: ARGX-109
- Clazakizumab
- Elsilimomab
- mAb 1339
- Olokizumab
- Sarilumab
- Siltuximab
- Sirukumab
- Tocilizumab
- Levilimab
|
---|
IL-7 | |
---|
IL-8 |
- See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
|
---|
IL-9 | |
---|
IL-10 | |
---|
IL-11 | |
---|
IL-12 |
- Antibodies: Briakinumab
- Ustekinumab
|
---|
IL-13 |
- Antibodies: Anrukinzumab
- Lebrikizumab
- Tralokinumab
|
---|
IL-15 | |
---|
IL-17 |
- Antibodies: Brodalumab
- Ixekizumab
- Perakizumab
- Remtolumab
- Secukinumab
- Vunakizumab
|
---|
| |
---|
IL-20 |
- Antibodies: Fletikumab (against IL-20)
|
---|
IL-21 |
- Antibodies: NNC0114-0005
- NNC0114-0006
|
---|
IL-22 |
- Antibodies: Fezakinumab (against IL-22)
|
---|
IL-23 |
- Agonists: Interleukin 23 (SGRF)
- Antibodies: Brazikumab
- Briakinumab
- Guselkumab
- Risankizumab
- Tildrakizumab
- Ustekinumab
|
---|
IL-27 | |
---|
IL-28 | |
---|
IL-31 | |
---|
IL1RL1 | |
---|
IL1RL2 | |
---|
Others | JAK | |
---|
Others |
- Unsorted: Efavaleukin alfa
- Efineptakin alfa
|
---|
|
---|